Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methoxymorpholino doxorubicin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Methoxymorpholino doxorubicin is a derivative of doxorubicin, which belongs to the anthracycline and antitumor antibiotic family of medications. As a doxorubicin analog, it likely works by interfering with DNA function, slowing or stopping the growth of cancer cells. The methoxymorpholino modification may alter the pharmacokinetic properties or targeting capabilities of the original doxorubicin molecule.
02
Targets
DNA
Beyond the preview
Go deeper on methoxymorpholino doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methoxymorpholino doxorubicin.